Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.9
5.2
Journals
Vaccines
Special Issues
Immune Correlates of Protection in Vaccines, 2nd Edition
share announcement

Immune Correlates of Protection in Vaccines, 2nd Edition

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Innate and Adaptive Immunity in Vaccination".

Deadline for manuscript submissions: 16 August 2025 | Viewed by 1239

Special Issue Editor

Dr. Jingyou Yu

E-Mail Website
Guest Editor
Division of Drug and Vaccine Research, Guangzhou Laboratory, State Key Laboratory of Respiratory Disease, Guangzhou Medical University, Guangzhou 510320, China
Interests: vaccine development; oncolytic viral therapy; virus–host interaction; innate immunity; viral entry
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Characterizing immune correlates of protection is necessary to inform our understanding of pathogenesis and guide vaccine development. Previous vaccine efforts have underscored the crucial roles of both humoral and cellular immunity against viral pathogens and cancers. However, antibodies represent the primary correlate of immunity for most licensed vaccines. This Special Issue aims to expand our knowledge of immune responses, elicited naturally or by vaccination, and their contribution to protective efficacy. We cordially invite research articles and reviews that define the correlates of protection to distinguish between surrogates versus mechanisms of immunity. This Special Issue will cover the challenges that have emerged in determining the immune correlates of protection in vaccines, including innate immunity, B and T cell trained immunity, and so forth. We hope that these highlights will inform superior next-generation vaccine design.

Dr. Jingyou Yu
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • vaccine
  • humoral immunity
  • cellular immunity
  • innate immunity
  • infectious disease
  • virus
  • cancer

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

15 pages, 3583 KiB  
Article
Synthetic rEg.P29 Peptides Induce Protective Immune Responses Against Echinococcus granulosus in Mice
by Yongxue Lv, Jing Tang, Tao Li, Yinqi Zhao, Changyou Wu and Wei Zhao
Vaccines 2025, 13(3), 266; https://doi.org/10.3390/vaccines13030266 - 3 Mar 2025
Viewed by 891
Abstract
Background: Echinococcus granulosus represents a significant threat to animal husbandry and human health, but its consequences are often underestimated. Vaccination can prevent E. granulosus infection. We investigated the immune protective effect induced by the recombinant protein P29 of E. granulosus (rEg.P29) peptide vaccine. [...] Read more.
Background: Echinococcus granulosus represents a significant threat to animal husbandry and human health, but its consequences are often underestimated. Vaccination can prevent E. granulosus infection. We investigated the immune protective effect induced by the recombinant protein P29 of E. granulosus (rEg.P29) peptide vaccine. Methods: The CD4+ T-, CD8+ T-, Treg-, and CD8+CD107a+ T-cell proportions in the spleen and peripheral blood of infected mice were analyzed using flow cytometry. Additionally, we measured the proportions of IFN-γ and IL-2 secreted by memory T cells, CD19+CD138−B cells, CD19+CD138+ plasmablasts, CD19−CD138+ plasma cells, and CD19+IgD−IgG+ and CD19+IgD−IgA+ memory B cells. Results: No significant differences were noted in CD4+ T-, CD8+ T-, and CD8+CD107a+ Treg-cell percentages among the experimental groups. However, IFN-γ, IL-2, and TNF-α levels and vaccine-specific antibody concentrations in the plasma were significantly elevated in the rEg.P29T+B + CpG + infection and rEg.P29 + CpG + infection groups compared to those in the PBS + infection and CpG + infection groups. Similarly, CD19−CD138+ plasma cell and CD19+IgD−IgG+ and CD19+IgD−IgA+ memory B-cell populations, along with specific antibodies, were significantly higher in these groups. Especially, the average cyst burden in the rEg.P29T+B + CpG + infection and rEg.P29 + CpG + infection groups was significantly reduced compared to that in the PBS + infection and CpG + infection groups. Conclusions: Synthetic peptide vaccines targeting rEg.P29 can effectively inhibit cysts, offering a novel strategy for the development of vaccines against E. granulosus. These findings provide a foundation for further research on the immunogenicity and protective efficacy of rEg.P29-based vaccines. Full article
(This article belongs to the Special Issue Immune Correlates of Protection in Vaccines, 2nd Edition)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop